CAS No.: 1202055-32-0
N-(2,6-Diethylphenyl)-1-methyl-8-((4-((1-methylpiperidin-4-yl)carbamoyl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide Catalog No. CSN17553
NMS-P715 is the first selective, ATP-competitive and orally bioavailable MPS1 small-molecule inhibitor (IC50=8 nM) and selectively reduces cancer cell proliferation, leaving normal cells almost unaffected.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
- 参考文献
- [1] Colombo R, Caldarelli M, et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res. 2010 Dec 15;70(24):10255-64.
- [2] Slee RB, Grimes BR, et al. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715. Mol Cancer Ther. 2014 Feb;13(2):307-315.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 1202055-32-0 | 储存条件 |
|
|||
| 分子式 | C35H39F3N8O3 | 运输 | 蓝冰 | |||
| 分子量 | 676.73 | 别名 | ||||
| 溶解度 |
|
动物实验配方 |
